PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16144885

Antipsychotic polypharmacy: do benefits justify the risks?

Andre M Tapp·Amanda Ernst Wood·Nael Kilzieh·Annette Kennedy·Murray A Raskind
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Antipsychotic AgentsDrug Therapy, CombinationHumansPsychotic DisordersRetrospective StudiesRiskSchizophreniaLetter

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Andre M Tapp, Amanda Ernst Wood, Nael Kilzieh, Annette Kennedy, Murray A Raskind. 2005-09-06. Antipsychotic polypharmacy: do benefits justify the risks?. https://doi.org/10.1345/aph.1e429

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Differential pharmacology of atypical antipsychotics: clinical implications.

PURPOSE: Pharmacology of atypical antipsychotics and the clinical implications are reviewed. SUMMARY: Psychiatric disorders, such as schizophrenia and bipolar disorder, are often associated with poor outcomes. Atypical antipsychotics have become the standard of care for these disorders, and multiple agents have demonstrated efficacy for both acute and maintenance therapy. As a result of their differential pharmacologic properties, atypical antipsychotics have diverse clinical profiles, resulting in different liabilities for specific adverse events. These effects can, in turn, have an adverse impact on patient functionality, adherence to therapy, and overall health. CONCLUSION: Atypical antipsychotics have distinct pharmacological profiles which result in clinically meaningful differences in adverse effects. Clinicians should have a wide choice of agents available with which to optimize outcomes in the majority of patients with psychiatric disorders.

Antipsychotic Agents↗